Integumen PLC Labskin breakthrough clones 16 human skin swabs
05 September 2019 - 4:01PM
RNS Non-Regulatory
TIDMSKIN
Integumen PLC
05 September 2019
AIM share code: SKIN
5 September 2019
Integumen PLC
("Integumen" or "Company")
Labskin breakthrough clones 16 human skin swabs into 54 living
microbiome test subjects
Enables multiple skincare products or topical medical treatments
to be tested on the same subject
Integumen will present results of a new breakthrough Labskin
cloning study at the Microbiome AI conference in San Diego,
California, USA, later today.
Labskin scientists cloned 16 swabs of skin from the cheeks of
healthy volunteers into 54 Labskin test subjects to allow
sequencing of microbial DNA for the identification and
quantification of the bacterial microbiome isolated and pooled
together. The live bacteria, virus and fungi (microbiota) was
sustained on all 54 test subjects for up to 14 days in the Labskin
laboratories in York, UK.
The LabskinAI virtual model aggregated and analysed the
bacterial microbiome data, extracted from each sample, and after
eliminating false or anomalous readings, provided test results
within a range of +/-10% of the human volunteers' control skin from
which it was initially cloned.
The results of this study validate Labskin's ability to test
multiple clinical trial and skincare products in parallel, on the
cloned human skin microbiome, that is as close to the original
microbiome of a human test subject, without the need for human
volunteers after initial cloning takes place. This allows multiple
skincare products or topical drug samples to be tested on the same
subject, at the same time, thus substantially reducing development
time, clinical error and clinical trial supervision costs.
Gerard Brandon, CEO of Integumen plc, comments:
"By de-risking each stage of the traditional topical drug and
skincare product development process, the Labskin cloning service
makes it economic for industry to research and explore new
treatments by allowing agile development and a cost-effective "fast
fail" protocols on disposable human-skin test subjects cloned from
healthy human volunteers.
"This breakthrough study clearly supports our commercial
strategy and demonstrates Labskin's ability to deliver healthy and
damaged skin testing 'as services' using a proven 'software as a
service' business model already adopted by, and proven, in other
industries."
Contacts
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited Neil Baldwin/Andrew
(Nominated Adviser) Emmott +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments
(TPI) Limited (Broker) Andy Thacker +44 (0) 20 3621 4120
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated product and services
company for skin related diseases, treatments and therapies with
three business units:
-- Labskin AI's technology platform incorporates artificial
intelligence within clinical research for medical device,
pharmaceuticals, cosmeceuticals and related life science test
services. Labskin allows skincare, healthcare, pharmaceutical
manufacturers and cosmetic companies to test their products on
human-like skin in a real-world environment with full access to
multiple state-of-the-art partner technologies.
-- Wound pHase is developing skin and wound care products using
its proprietary wound dressing technology. Working in collaboration
with CBD providers creating a CBD infused diabetic wound care
product range.
-- Stoer-for-men skin products e-commerce division offers a
range of skincare products derived from 5 natural super-ingredient
plant extracts specifically for men to reduce the signs of ageing
and is also used as a control for client testing within Labskin
laboratories.
The Company combines data analytics with access to therapeutic
operational expertise and offers solutions to our clients, from
regulatory approvals, right through to marketing fully tested
ingredients that have been certified on our Laboratory grown living
human tissue.
About RNS Reach announcements:
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUSUNRKKAKRAR
(END) Dow Jones Newswires
September 05, 2019 02:01 ET (06:01 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024